Samsung Biologics launches high-concentration formulation platform to accelerate high-dose drug development
- Written by PR Newswire
 |
- S-HiConTM is designed to maximize drug delivery and stability through high-concentration formulation
- The platform can address challenges associated with viscosity and achieve stable liquid formulation for over 200 mg/mL subcutaneous administration
INCHEON, South Korea, Oct. 14, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global...
